GSK plc (LSE:GSK) is a British multinational pharmaceutical and biotechnology company founded in 1715, making it one of the world's oldest pharmaceutical companies. The company was formed through a series of mergers, most notably the 2000 merger of Glaxo Wellcome and SmithKline Beecham, and changed its name from GlaxoSmithKline plc to GSK plc in May 2022. Headquartered in Brentford, United Kingdom, GSK has evolved from a traditional pharmaceutical company into a focused biopharmaceutical enterprise specializing in vaccines and specialty medicines. The company operates globally with significant presence in the United States, Europe, and emerging markets, dedicating its efforts to preventing and treating diseases through innovative research and development.
$49.46
−0.10%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$49.44
From 52W high−19.16%
Volume5.11M
Market cap$99.09B
P/E (TTM)15.5x
P/S (TTM)2.2x
Div yield3.67%
Key dataOct 19, 2026
Open
$49.44
From 52W high
−19.16%
Volume
5.11M
Market cap
$99.09B
ValuationView details →
P/E (Fwd)
9.7x
EV/EBITDA
10.1x
P/E (TTM)
15.5x
RSI (14)
56.4
MomentumView details →
1D Return
−0.10%
YTD Return
+1.02%
SummaryUpdated Jun 1, 2026
Latest newsMore news →
GSK plc reported early-stage trial results for risvutatug rezetecan, with confirmed responses in 11 of 18 patients at 8 mg/kg and seven of 22 patients at 6 mg/kg.15h agoGSK plc reported that its B7-H3-targeted antibody-drug conjugate Ris-Rez achieved a 61% objective response rate in a lung cancer clinical trial.23h agoChia Tai Tianqing said its strategic-cooperation product Bepirovirsen was selected for two oral presentations and eight poster presentations at the 2026 AASLD annual meeting.5d ago